MX2021012449A - Metodo para tratar tumores. - Google Patents
Metodo para tratar tumores.Info
- Publication number
- MX2021012449A MX2021012449A MX2021012449A MX2021012449A MX2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A
- Authority
- MX
- Mexico
- Prior art keywords
- treating tumours
- treating
- tumors
- epoxytiglienone
- abscopal
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901280A AU2019901280A0 (en) | 2019-04-12 | Method of Treatment | |
| PCT/AU2020/050360 WO2020206504A1 (en) | 2019-04-12 | 2020-04-09 | Method of treating tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012449A true MX2021012449A (es) | 2021-11-12 |
Family
ID=72752169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012449A MX2021012449A (es) | 2019-04-12 | 2020-04-09 | Metodo para tratar tumores. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12226391B2 (https=) |
| EP (1) | EP3952858B1 (https=) |
| JP (2) | JP2022528915A (https=) |
| KR (1) | KR20210152531A (https=) |
| CN (1) | CN113924091A (https=) |
| AU (1) | AU2020256847B2 (https=) |
| BR (1) | BR112021020253A2 (https=) |
| CA (1) | CA3136216C (https=) |
| DK (1) | DK3952858T3 (https=) |
| EA (1) | EA202192757A1 (https=) |
| ES (1) | ES3063750T3 (https=) |
| FI (1) | FI3952858T3 (https=) |
| HR (1) | HRP20260232T1 (https=) |
| IL (1) | IL287210B2 (https=) |
| LT (1) | LT3952858T (https=) |
| MX (1) | MX2021012449A (https=) |
| MY (1) | MY208979A (https=) |
| PL (1) | PL3952858T3 (https=) |
| PT (1) | PT3952858T (https=) |
| RS (1) | RS67777B1 (https=) |
| SG (1) | SG11202110599RA (https=) |
| SI (1) | SI3952858T1 (https=) |
| SM (1) | SMT202600066T1 (https=) |
| UA (1) | UA129840C2 (https=) |
| WO (1) | WO2020206504A1 (https=) |
| ZA (1) | ZA202108677B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597019A (en) * | 2005-12-23 | 2013-11-29 | Qbiotics Ltd | Tiglien-3-one derivatives |
| JP7013753B2 (ja) * | 2017-09-15 | 2022-02-01 | 株式会社三洋物産 | 遊技機 |
| IL289072B2 (en) | 2019-06-19 | 2025-06-01 | QBiotics Pty Ltd | Biofilm disruption |
| JP2024546296A (ja) * | 2021-12-21 | 2024-12-19 | キューバイオティクス プロプライアタリー リミティド | 結晶性中間体 |
| CN120569368A (zh) * | 2022-12-21 | 2025-08-29 | Q生物股份有限公司 | 晶型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597019A (en) * | 2005-12-23 | 2013-11-29 | Qbiotics Ltd | Tiglien-3-one derivatives |
| UA118670C2 (uk) * | 2013-04-18 | 2019-02-25 | К'Юбайотікс Лімітед | Способи та композиції для загоєння ран |
| JP2019523303A (ja) * | 2016-07-28 | 2019-08-22 | キューバイオティクス リミティド | 治療方法 |
| CN110461324A (zh) | 2017-03-23 | 2019-11-15 | Q生物股份有限公司 | 用于治疗或预防肿瘤的联合疗法 |
-
2020
- 2020-04-09 AU AU2020256847A patent/AU2020256847B2/en active Active
- 2020-04-09 KR KR1020217036942A patent/KR20210152531A/ko active Pending
- 2020-04-09 JP JP2021559659A patent/JP2022528915A/ja active Pending
- 2020-04-09 FI FIEP20787143.5T patent/FI3952858T3/fi active
- 2020-04-09 HR HRP20260232TT patent/HRP20260232T1/hr unknown
- 2020-04-09 CN CN202080042217.2A patent/CN113924091A/zh active Pending
- 2020-04-09 UA UAA202106322A patent/UA129840C2/uk unknown
- 2020-04-09 WO PCT/AU2020/050360 patent/WO2020206504A1/en not_active Ceased
- 2020-04-09 LT LTEPPCT/AU2020/050360T patent/LT3952858T/lt unknown
- 2020-04-09 EA EA202192757A patent/EA202192757A1/ru unknown
- 2020-04-09 PL PL20787143.5T patent/PL3952858T3/pl unknown
- 2020-04-09 DK DK20787143.5T patent/DK3952858T3/da active
- 2020-04-09 ES ES20787143T patent/ES3063750T3/es active Active
- 2020-04-09 RS RS20260210A patent/RS67777B1/sr unknown
- 2020-04-09 SG SG11202110599RA patent/SG11202110599RA/en unknown
- 2020-04-09 SM SM20260066T patent/SMT202600066T1/it unknown
- 2020-04-09 CA CA3136216A patent/CA3136216C/en active Active
- 2020-04-09 IL IL287210A patent/IL287210B2/en unknown
- 2020-04-09 EP EP20787143.5A patent/EP3952858B1/en active Active
- 2020-04-09 MY MYPI2021005947A patent/MY208979A/en unknown
- 2020-04-09 US US17/602,909 patent/US12226391B2/en active Active
- 2020-04-09 SI SI202030731T patent/SI3952858T1/sl unknown
- 2020-04-09 BR BR112021020253A patent/BR112021020253A2/pt unknown
- 2020-04-09 PT PT207871435T patent/PT3952858T/pt unknown
- 2020-04-09 MX MX2021012449A patent/MX2021012449A/es unknown
-
2021
- 2021-11-05 ZA ZA2021/08677A patent/ZA202108677B/en unknown
-
2024
- 2024-12-27 JP JP2024231893A patent/JP2025060945A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3952858T (lt) | 2026-04-10 |
| US20220193023A1 (en) | 2022-06-23 |
| IL287210B2 (en) | 2025-07-01 |
| AU2020256847A1 (en) | 2021-11-11 |
| PT3952858T (pt) | 2026-02-26 |
| IL287210B1 (en) | 2025-03-01 |
| SG11202110599RA (en) | 2021-10-28 |
| CA3136216A1 (en) | 2020-10-15 |
| CN113924091A (zh) | 2022-01-11 |
| EP3952858A1 (en) | 2022-02-16 |
| EP3952858B1 (en) | 2025-12-17 |
| ES3063750T3 (en) | 2026-04-20 |
| WO2020206504A1 (en) | 2020-10-15 |
| SMT202600066T1 (it) | 2026-03-09 |
| JP2022528915A (ja) | 2022-06-16 |
| ZA202108677B (en) | 2026-03-25 |
| AU2020256847B2 (en) | 2025-05-15 |
| IL287210A (en) | 2021-12-01 |
| US12226391B2 (en) | 2025-02-18 |
| DK3952858T3 (da) | 2026-02-23 |
| RS67777B1 (sr) | 2026-03-31 |
| JP2025060945A (ja) | 2025-04-10 |
| MY208979A (en) | 2025-06-14 |
| HRP20260232T1 (hr) | 2026-03-27 |
| PL3952858T3 (pl) | 2026-03-30 |
| EA202192757A1 (ru) | 2022-02-11 |
| FI3952858T3 (fi) | 2026-02-18 |
| CA3136216C (en) | 2024-01-16 |
| EP3952858A4 (en) | 2022-05-25 |
| KR20210152531A (ko) | 2021-12-15 |
| UA129840C2 (uk) | 2025-08-20 |
| BR112021020253A2 (pt) | 2021-12-07 |
| SI3952858T1 (sl) | 2026-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012449A (es) | Metodo para tratar tumores. | |
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| CO2018003542A2 (es) | Anticuerpo anti-garp | |
| CO2017007662A2 (es) | Terapias de combinación para el tratamiento de cánceres | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| EA201791951A1 (ru) | Продукты рилузола и их применение | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2015008898A (es) | Metodos para el tratamiento de cancer pancreatico. | |
| NI201900105A (es) | Terapia combinada para el cáncer de próstata | |
| MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
| MX2017012408A (es) | Metodos para administrar inhibidores de glutaminasa. | |
| PH12018501451A1 (en) | Formulations for treating bladder cancer | |
| MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
| MX390835B (es) | Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| MX386249B (es) | Terapia tusc2 para usarse en el tratamiento de cáncer. | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| BR112019005825A2 (pt) | vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| MX2020003830A (es) | Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos. | |
| MX2018008196A (es) | Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional. |